Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Ero1aem1/Cya
Common Name:
Ero1a-KO
Product ID:
S-KO-10193
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Ero1a-KO
Strain ID
KOCMP-50527-Ero1a-B6J-VA
Gene Name
Ero1a
Product ID
S-KO-10193
Gene Alias
ERO1-L; Ero1l
Background
C57BL/6JCya
NCBI ID
50527
Modification
Conventional knockout
Chromosome
14
Phenotype
MGI:1354385
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Ero1aem1/Cya mice (Catalog S-KO-10193) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000022378
NCBI RefSeq
NM_015774
Target Region
Exon 2~8
Size of Effective Region
~8.5 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Ablation of ERO1A in tumor cells incites anti-tumor T cell immunity, promotes the efficacy of aPD-1, and induces lethal unfolded protein responses in tumor cells undergoing ER stress, enhancing anti-tumor immunity via immunogenic cell death [1]. In EGFR-mutated non-small cell lung cancer, ablating ERO1A expression affects clonogenicity, tumor sphere formation, and response to Osimertinib [2]. In SEPN1-related myopathy, ERO1A knockout in a mouse background of SEPN1 loss blunts ER stress and improves multiple MAM functions, reversing diaphragmatic weakness [3]. In Drosophila, genetic suppression or pharmacological inhibition of ERO1A homolog ERO1L provides neuroprotection under ER stress and ameliorates UBQLN2-ALS phenotypes [4]. In pancreatic ductal adenocarcinoma, inhibition of ERO1a improves monocyte infiltration and differentiation into dendritic cells [5]. In breast cancer, suppression of microglial ERO1a alleviates inflammation and enhances rehabilitative training efficacy post-ischemic stroke [6]. Small molecule-mediated inhibition of ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment [8]. Cordycepin reduces ERO1A expression, inhibiting lipid metabolism and metastasis in cholangiocarcinoma [9].

In conclusion, ERO1A plays a crucial role in protein folding and redox regulation within the ER. Its ablation or inhibition in various model systems has revealed its significance in cancer, myopathy, neurodegenerative diseases, and stroke-related conditions. These model-based studies, especially gene knockout experiments, have provided insights into the potential of targeting ERO1A for therapeutic intervention in multiple disease areas.

References:

1. Liu, Lihui, Li, Sini, Qu, Yan, Ma, Zixiao, Wang, Jie. 2023. Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. In Cell reports. Medicine, 4, 101206. doi:10.1016/j.xcrm.2023.101206. https://pubmed.ncbi.nlm.nih.gov/37769655/

2. Voronkova, M A, Johnson, B, Gandhi, N, Halmos, B, Hazlehurst, L A. 2024. ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer. In NPJ precision oncology, 8, 250. doi:10.1038/s41698-024-00736-1. https://pubmed.ncbi.nlm.nih.gov/39496753/

3. Germani, Serena, Van Ho, Andrew Tri, Cherubini, Alessandro, Ferreiro, Ana, Zito, Ester. 2024. SEPN1-related myopathy depends on the oxidoreductase ERO1A and is druggable with the chemical chaperone TUDCA. In Cell reports. Medicine, 5, 101439. doi:10.1016/j.xcrm.2024.101439. https://pubmed.ncbi.nlm.nih.gov/38402623/

4. Yeewa, Ranchana, Sangphukieo, Apiwat, Jantaree, Phatcharida, Lo Piccolo, Luca, Jantrapirom, Salinee. 2024. ERO1A inhibition mitigates neuronal ER stress and ameliorates UBQLN2ALS phenotypes in Drosophila melanogaster. In Progress in neurobiology, 242, 102674. doi:10.1016/j.pneurobio.2024.102674. https://pubmed.ncbi.nlm.nih.gov/39395630/

5. Tay, Apple Hui Min, Cinotti, Riccardo, Sze, Newman Sui Kwan, Lundqvist, Andreas. 2023. Inhibition of ERO1a and IDO1 improves dendritic cell infiltration into pancreatic ductal adenocarcinoma. In Frontiers in immunology, 14, 1264012. doi:10.3389/fimmu.2023.1264012. https://pubmed.ncbi.nlm.nih.gov/38187398/

6. Ren, Jing, Lv, Yuan, Tian, Qiuyan, Feng, Xing, Ding, Xin. 2023. Suppression of Microglial ERO1a Alleviates Inflammation and Enhances the Efficacy of Rehabilitative Training After Ischemic Stroke. In Molecular neurobiology, 60, 4429-4441. doi:10.1007/s12035-023-03333-8. https://pubmed.ncbi.nlm.nih.gov/37100971/

7. Shergalis, Andrea G, Hu, Shuai, Bankhead, Armand, Neamati, Nouri. 2020. Role of the ERO1-PDI interaction in oxidative protein folding and disease. In Pharmacology & therapeutics, 210, 107525. doi:10.1016/j.pharmthera.2020.107525. https://pubmed.ncbi.nlm.nih.gov/32201313/

8. Varone, Ersilia, Retini, Michele, Cherubini, Alessandro, Cantoni, Orazio, Zito, Ester. 2025. Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment. In Cell death & disease, 16, 105. doi:10.1038/s41419-025-07426-1. https://pubmed.ncbi.nlm.nih.gov/39962052/

9. Zhou, Xuebing, Li, Yuan, Yang, Chunyu, Peng, Bosen, Ren, Xiangshan. 2023. Cordycepin reprogramming lipid metabolism to block metastasis and EMT via ERO1A/mTOR/SREBP1 axis in cholangiocarcinoma. In Life sciences, 327, 121698. doi:10.1016/j.lfs.2023.121698. https://pubmed.ncbi.nlm.nih.gov/37080351/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest